Filing Details
- Accession Number:
- 0001714899-25-000149
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-07-11 17:13:23
- Reporting Period:
- 2025-07-09
- Filing Date:
- 2025-07-11
- Accepted Time:
- 2025-07-11 17:13:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1724310 | J. Ryan Watts | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Transaction Summary
| Sold: | 495,282 shares | Avg. Price: $15.00 | Total Value: $7,429,230.00 |
| Number of Shares After Transactions: | 253,071 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-07-09 | 455,282 | $0.68 | 708,353 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2025-07-09 | 40,000 | $5.28 | 748,353 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-07-09 | 495,282 | $15.00 | 253,071 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2025-07-09 | 455,282 | $0.00 | 455,282 | $0.68 |
| Common Stock | Stock Option (right to buy) | Disposition | 2025-07-09 | 40,000 | $0.00 | 40,000 | $5.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 622,809 | 2025-08-21 | No | 4 | M | Direct | |
| 20,369 | 2027-03-07 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,202,604 | Indirect | See footnote |
Footnotes
- Includes 177,940 Unvested RSUs.
- The sales reported by the Reporting Person were made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 09/16/2024. The shares sold primarily relate to 455,282 stock options that expire on 08/21/2025.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or asecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.
- 25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
